AVITA Medical (ASX:AVH) unveiled interim data from its Cohealyx-I multi-centre study, signalling a potential shift in the standard of care for full-thickness wounds.
The results, presented during the American Burn Association annual meeting, demonstrate that the use of Cohealyx accelerates the preparation of wound beds, reducing the mean time to skin grafting to just 13.6 days.
This represents a nearly 20-day improvement over the real-world literature-derived benchmark of 33.2 days, achieving high statistical significance (p < 0.001).
The analysis, which tracked 40 patients, found a median grafting time of 11 days, with some procedures occurring as early as five days post-treatment.
72% of patients were ready for grafting within a fortnight. Clinical investigators reported a 90% satisfaction rate, emphasising the product’s ability to support rapid vascularisation across a myriad of complex wound types.
Derek Bell, MD, Director of the Kessler Burn Centre, noted that efficient wound bed preparation remains a primary challenge in trauma care, and these results suggest Cohealyx could establish a new clinical benchmark.
AVITA Medical's Interim CEO, Cary Vance, expressed confidence that this "differentiated solution" will drive broader adoption by improving critical stages of the healing pathway.